Waystar Secures Favorable Terms in Term Loan Repricing, Supports Iodine Software Acquisition

Reuters
Aug 13
Waystar Secures Favorable Terms in Term Loan Repricing, Supports Iodine Software Acquisition

Waystar Holding Corp. (Nasdaq: WAY), a prominent provider of healthcare payment software, has announced a successful repricing of its first lien term loan, originally due in October 2029. The company has secured more favorable terms with a reduced interest rate of adjusted SOFR +2.00%, marking a 25-basis-point reduction from previous terms. This move comes amid strong demand from both new and existing lenders, highlighting confidence in Waystar's solid financial standing and cash flow generation. Additionally, Waystar will incorporate $250 million in incremental term loans under the same terms, contingent upon the closing of the Iodine Software acquisition. This strategic financial adjustment aims to support Waystar's growth strategy and competitive edge, with reassurances from S&P, Moody's, and Fitch, who have reaffirmed the company's debt rating and stable outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waystar Holding Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY50206) on August 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10